Associated Banc-Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Associated Banc-Corp’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,915	Closed	-$316K	–	282
2016 Q1	$316K	Hold	5,915	–	–	0.02%	243
2015 Q4	$389K	Hold	5,915	–	–	0.03%	229
2015 Q3	$334K	Hold	5,915	–	–	0.02%	237
2015 Q2	$350K	Sell	5,915 -200	-3%	-$12.3K	0.02%	237
2015 Q1	$381K	Buy	6,115 +2,005	+49%	+$117K	0.02%	232
2014 Q4	$237K	Buy	4,110 +100	+2%	+$5.57K	0.02%	250
2014 Q3	$215K	Sell	4,010 -10,128	-72%	-$537K	0.01%	253
2014 Q2	$741K	Sell	14,138 -901	-6%	-$46.1K	0.05%	183
2014 Q1	$794K	Sell	15,039 -9,339	-38%	-$432K	0.05%	174
2013 Q4	$977K	Sell	24,378 -42,155	-63%	-$1.66M	0.07%	164
2013 Q3	$2.51M	Sell	66,533 -60,332	-48%	-$2.35M	0.2%	113
2013 Q2	$4.97M	Buy	+126,865	New	+$4.94M	0.41%	73

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Associated Banc-Corp's TEVA Position: Q2 2016 in Review

Associated Banc-Corp sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 5,915 shares — an estimated $316K sold.

Associated Banc-Corp first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $4.97M in Q2 2013. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Associated Banc-Corp reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Associated Banc-Corp sold 5,915 Teva Pharmaceuticals shares in Q2 2016, an estimated $316K.
Associated Banc-Corp first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Associated Banc-Corp's Teva Pharmaceuticals position peaked at $4.97M in Q2 2013.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Associated Banc-Corp's 13F filing for Q2 2016, filed 11 Aug 2016.